Hormone dependence of mammary tumors induced in rats by intraperitoneal NMU injection

Cancer Investigation

Volumn 15, Issue 1, 1997, Pages 8-17

  Martin, Gabriela ^a   Davio, Carlos ^a   Rivera, Elena ^a   Melito, Graciela ^a   Cricco, Graciela ^a   Andrade, Nélida ^a   Caro, Ricardo ^a   Bergoc, Rosa ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

hormone dependence; mammary tumors; N nitroso N methylurea; rats

Indexed keywords

BROMOCRIPTINE; ESTRADIOL; HALOPERIDOL; METHYLNITROSOUREA; PROGESTERONE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031023366     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709018912     Document Type: Article

References (52)

1. Huggins SC, Briziarelli G, Sutton R: Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors. J Exp Med 109:25-43, 1959.
2. Dickson RZ, Rosen N, Gelmann EF, et al: Receptor and signal transduction related protooncogenes in breast cancer. TIPS 8:372-373, 1987.
3. Chalbos D, Vignon F, Keydar I, et al: Estrogens stimulate cell proliferation and induce secretory protein in human breast cancer cell line. J Clin Endocrinol Metab 55:276-283, 1982.
4. Kaichowski DA, Sager R, Webster L: Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing recombinant estrogen receptors. Cancer Res 53:5004-5011, 1993.
5. Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogen: Problem and potential for future clinical applications. Breast Cancer Res Treat 3(Suppl):73-86, 1983.
6. Pruit BT, Rose DP: Pituitary control of nitrosomethylurea-induced rat mammary tumor growth. Program of the 63rd. Annual Meeting of the Endocrine Society, Cincinnati, 1981, p 246 (abstract).
7. Liher JG, Avits TA, Randerath E, Randerath K: Estrogen-induced endogenous DNA aduction: Possible mechanisme of hormonal cancer. Proc. Natl Acad Sci USA 83:5301, 1986.
8. Leung BS, Sakaki GH, Leungs JS: Estrogen prolactin dependency in 7-12 dimethylbenzo[a] antracene-induced mammary tumors in rats. Cancer Res 31:1051-1053, 1971.
9. Minasian-Batmanian LC, Jabara AG: Hormone and drug effect on growth of DMBA mammary tumors and plasma prolactine levels in adreno-ovariectomized rats. Br J Cancer 43:832-841, 1981.
10. Gullino PM, Pettigrew HM, Grantam FH: N-Nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst 54:401-409, 1975.
11. Ratko TH, Braun RJ, Pezzuto JM, et al: Estrous cycle modification of rat mammary gland DNA alkylation by N-methyl-N-nitrosourea. Cancer Res 48:3090-3095, 1988.
12. McCornick DL, Adamowski CR, Fiks A, et al: Dose response relationship for mammary tumor induction by a single administration of N-methyl-N-nitrosourea. Cancer Res 41:1690-1694, 1981.
13. Rose DP, Noonan JJ: Hormone dependence of rat mammary tumors induced by N-nitrosomethylurea. Eur J Cancer Clin Oncol 15: 1557-1558, 1981.
14. Turkot-Lemay L, Kelly PA: Characterization of estradiol, progesterone and prolactine receptors in nitrosomethylurea-induced mammary tumors and effect of antiestrogenic treatment on the development and growth of these tumors. Cancer Res 40:3232-3240, 1980.
15. Rose BP, Pruit B, Stauber P, et al: Influence of dosage schedule on the biological characteristics of N-nitroso-methylurea-induced rat mammary tumors. Cancer Res 40:235-238, 1980.
16. Arafah BM, Finegas HM, Roe J, et al: Hormone dependency in N-nitrosomethylurea-induced rat mammary tumors. Endocrinology 111:584-588, 1982.
17. Welch CW, Brown CK, Goodrich-Smith M, et al: Synergistic effect of chronic prolactin suppression and retinoic treatment in the prophylaxis of N-methyl-N-nitrosourea-induced mammary tumorogenesis in female Sprague-Dawley rats. Cancer Res 40:3095-3098, 1980.
18. Rivera ES, Andrade N, Martin G, et al: Induction of mammary tumors in rat by intraperitoneal injection of NMU: Histopathology and estral cycle influence. Cancer Lett 86:223-228, 1994.
19. Dominguez HE, Vidai NA, Fernandez BE: Effects of oophorectomy and sexual hormones on norepinephrine and epinephrine urinary excretion. Experientia 31:1103-1104, 1975.
20. Barnes CD, Eitherington IG: Drug Dosage in Laboratory Animals. Los Angeles, Los Angeles University of California Press, 1973, p 279.
21. Coluccia CA, Martin G, Melito G, et al: Hormonal study in NMU-induced tumor rais: Levamisol influence. Acta Bioq Clin Latinoam 23:375-379, 1989.
22. Steel R, Torrie J: Principles and Procedures of Statistics. New York, McGraw-Hill, 1960, p 110.
23. Hollander M, Wolf D: Non-parametric Statistical Methods. New York, Wiley, 1990.
24. Connover W: Practical Nonparametric Statistic. New York, Wiley, 1990.
25. Agresti A: Categorical Data Analysis. New York, Wiley, 1990.
26. Martín G, Rivera ES, Davio C, et al: Receptors characterization of intraperitoneally N-nitroso-N-methylurea-induced mammary tumors in rats. Cancer Lett 101:1-8, 1996.
27. Daniel CW, Silberstein GB, Strickland P: Direct action of 17β-estradiol on mouse mammary ducts analyzed sustained release implants and steroid autoradiography. Cancer Res 47:6052-6058, 1987.
28. Soto A, Bonnenschein C: Cell proliferation of estrogen-sensitive cells: The case for negative control. Endocrinol Rev 8:44-48, 1987.
29. Manni A, Wrigth C: Polyamines as mediators of estrogen action on the growth of experimental breast cancer in rats. J Natl Cancer Inst 73:511-514, 1984.
30. Jordan VC: Effect of tamoxifen (ICI 46, 474) on inhibition and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12:419-424, 1976.
31. Gottardis MM, Jordan VC: The antitumoral action of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020-4024, 1987.
32. Jordan VC, Dowse LJ : Tamoxifen as an antitumoral agent. I. Effect of estrogen binding. J Endocr 68:297-299, 1976.
33. Osborne CK, Boldt DH, Clark GM, et al: Effects of tamoxifen on human breast cancer cell cycle kinetic: accumulation of cells in early G1 phase. Cancer Res 43:3583-3585, 1983.
34. Welsch CW, Nagasawa H: Prolactin and murine mammary tumorogenesis: A review. Cancer Res 37:951-963, 1977.
35. Bradley CJ, Kledzik GS, Meiles J: Prolactin and estrogen dependency of rat mammary cancers at early and late stages of development. Cancer Res 36:319-324, 1976.
36. Anderson CH, Hussain RA, Han MC, et al: Estrous cycle dependence of nitroso-methylurea (NMU)-induced preneoplastic lesions in rat mammary gland. Cancer Lett 56:77-84, 1991.
37. Russo J, Russo IH: Influence of differentiation and cell kinetics in the susceptibility of rat mammary gland to carcinogencsis. Cancer Res 40:2677-2687, 1986.
38. Chen CL, Meites J: Effects of estrogen and progesterone on serum and pituitary prolactin levels in ovariectomized rats. Endocrinology 85:503-505, 1970.
39. Zajchowski D, Sajer R, Webster L: Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res 53:5004-5011, 1993.
40. Kiedzik GS, Bradley CJ, Maites J: Reduction of carcinogen-induced mammary cancer incidence in rats by early treatment with hormones or drugs. Cancer Res 34:2953-2956, 1974.
41. Bakker GM, Setyono-Han B, Henkelman MS, et al: Comparison of the action of the antiprogestin mifepristone (RU 486), the progestine megestrol acetate, the LHRH analog and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep 71:1021-1027, 1987.
42. Maas H, Jonat W, Stolzenbach G, et al: The problem of non-responding estrogen-receptor positive patients with advanced breast cancer. Cancer 6:2835-2837, 1980.
43. Clarke R, Thompson EW, Leonessa F, et al: Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat 24:227-239, 1993.
44. Raam S, Robert N, Pappas C, et al: Defective estrogen receptors in human mammary cancers: Their significance in defining hormone dependence. J Natl Cancer Inst 80:756-761, 1988.
45. Clarke R, Lippman ME: Antiestrogen resistance: mechanisms and reversal. In: Drug Resistance in Oncology, edited by BA Teicher, Marcel Dekker, 1992, pp 501-536.
46. Horwitz K: Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat 26:119-130, 1993.
47. Karnik PS, Kulkarni S, Liu X, et al: Estrogen receptor mutation in tamoxifen-resistant breast cancer. Cancer Res 54:345-355, 1994.
48. Jordan VC: Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat 15:125-136, 1990.
49. Sutherland RL, Foo MS: Differential binding of antiestrogen by rat uterine and chick oviduct cytosol. Biochem Biophys Res Commun 91:183-191, 1979.
50. Brünner N, Moser C, Clarke R, et al: IGF-I and IGF-II expression in human breast cancer xenographs: Relationship to hormone independence. Breast Cancer Res Treat 22:39-45, 1992.
51. Pollak MN, Huyth H, Lefebre SP: Tamoxifen reduces serum insuline-like growth factor I (IGF-I). Cancer Res Treat 22:91-100, 1992.
52. Haran EF, Maretzeck AF, Goldemberg E, et al: Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 54:5511-5514, 1994.